Show simple item record

dc.contributor.authorHaering, Matthias
dc.contributor.authorHördt, Andreas
dc.contributor.authorMüller, A
dc.contributor.authorHernandez-Vargas, Esteban Abelardo
dc.date.accessioned2014-07-11T13:32:02Zen
dc.date.available2014-07-11T13:32:02Zen
dc.date.issued2014en
dc.identifier.citationComputational Study to Determine When to Initiate and Alternate Therapy in HIV Infection. 2014, 2014:472869 Biomed Res Inten
dc.identifier.issn2314-6141en
dc.identifier.pmid24900966en
dc.identifier.doi10.1155/2014/472869en
dc.identifier.urihttp://hdl.handle.net/10033/322819en
dc.description.abstractHIV is a widespread viral infection without cure. Drug treatment has transformed HIV disease into a treatable long-term infection. However, the appearance of mutations within the viral genome reduces the susceptibility of HIV to drugs. Therefore, a key goal is to extend the time until patients exhibit resistance to all existing drugs. Current HIV treatment guidelines seem poorly supported as practitioners have not achieved a consensus on the optimal time to initiate and to switch antiretroviral treatments. We contribute to this discussion with predictions derived from a mathematical model of HIV dynamics. Our results indicate that early therapy initiation (within 2 years postinfection) is critical to delay AIDS progression. For patients who have not received any therapy during the first 3 years postinfection, switch in response to virological failure may outperform proactive switching strategies. In case that proactive switching is opted, the switching time between therapies should not be larger than 100 days. Further clinical trials are needed to either confirm or falsify these predictions.
dc.language.isoenen
dc.rightsArchived with thanks to BioMed research internationalen
dc.titleComputational Study to Determine When to Initiate and Alternate Therapy in HIV Infection.en
dc.typeArticleen
dc.identifier.journalBioMed research internationalen
refterms.dateFOA2018-06-13T04:24:44Z
html.description.abstractHIV is a widespread viral infection without cure. Drug treatment has transformed HIV disease into a treatable long-term infection. However, the appearance of mutations within the viral genome reduces the susceptibility of HIV to drugs. Therefore, a key goal is to extend the time until patients exhibit resistance to all existing drugs. Current HIV treatment guidelines seem poorly supported as practitioners have not achieved a consensus on the optimal time to initiate and to switch antiretroviral treatments. We contribute to this discussion with predictions derived from a mathematical model of HIV dynamics. Our results indicate that early therapy initiation (within 2 years postinfection) is critical to delay AIDS progression. For patients who have not received any therapy during the first 3 years postinfection, switch in response to virological failure may outperform proactive switching strategies. In case that proactive switching is opted, the switching time between therapies should not be larger than 100 days. Further clinical trials are needed to either confirm or falsify these predictions.


Files in this item

Thumbnail
Name:
Haering et al_final.pdf
Size:
1.917Mb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record